Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Bachy, Emmanuel , Ghesquières, Hervé , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Allmer, Cristine, Chassagne‐Clément, Catherine, Nicolas‐Virelizier, Emmanuelle , Sebban, Catherine, Lebras, Laure , Macon, William R. , Feldman, Andrew L. , Syrbu, Sergei , Traverse‐Glehan, Alexandra, Coiffier, Bertrand , Weiner, George J. , Salles, Gilles , Link, Brian K. , Maurer, Matthew J. , Sarkozy, Clémentine , Slager, Susan L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R. , Feldman, Andrew L , Link, Brian K , Salles, Gilles A , Weiner, George , Bachy, Emmanuel , Syrbu, Sergei

Mayo Clinic

American Journal of Hematology | July 28, 2016 | Volume: 91 | Issue: 11 | Pages: 1096-1101

10.1002/ajh.24492 | PMID 27465588 Get It

Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1‐3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002‐2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re‐treatment, or death due to any cause. OS was compared to age‐and‐sex‐matched survival in the general US population using standardized mortality ratios (SMR) and 95% confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR = 3.72, 95%CI: 2.78‐4.88; Lyon SMR = 8.74, 95%CI: 5.41‐13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR = 0.73, 95%CI: 0.56‐0.94, Lyon SMR = 1.02, 95%CI: 0.58‐1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR = 17.63, 95%CI:11.97‐25.02, Lyon SMR = 19.10, 95%CI:9.86‐33.36; EFS24 failure: MER SMR = 13.02, 95%CI:9.31‐17.74, Lyon SMR = 7.22, 95%CI:4.13‐11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL. Am. J. Hematol. 91:1096–1101, 2016. © 2016 Wiley Periodicals, Inc.
Technique for 3-Dimesional (3D) Modeling of Osteoarticular Medial Femoral Condyle Vascularized Grafting to Replace the Proximal Pole of Unsalvagable Scaphoid Nonunions
Matsumoto, Jane M., Shin, Alexander Y. , Houdek, Matthew T. , Morris, Jonathan M. , Bishop, Allen T. , Shin, Alexander Y

Mayo Clinic

Techniques in Hand & Upper Extremity Surgery | July 27, 2016 | Volume: 20 | Issue: 3 | Pages: 117-124

10.1097/bth.0000000000000129 | PMID 27466049 Get It

This study describes a novel technique for the preoperative surgical planning for an osteoarticular medial femoral condyle (MFC) graft to replace the proximal pole of a scaphoid. In cases of proximal pole scaphoid nonunion or in Preiser disease, fragmentation of the articular surface can occur, leading to significant pain and disability. Osteoarticular MFC bone grafting can be used to treat these injuries by providing a vascularized osteoarticular surface. Using 3-dimensional imaging and printing we are able to precisely model the injured scaphoid, and also accurately plan the harvest of MFC osteoarticular graft. This technique allows for accurate preoperative planning of a complex 3-dimensional bone, and has improved our execution of the plan intraoperatively.
Chronic invasive fungal sinusitis: characterization and shift in management of a rare disease
D’Anza, Brian , Stokken, Janalee K., Greene, J. Scott , Kennedy, Thomas L., Woodard, Troy D. , Sindwani, Raj , Stokken, Janalee K. , Carlson, Matthew L

Mayo Clinic

International Forum of Allergy & Rhinology | July 27, 2016 | Volume: 6 | Issue: 12 | Pages: 1294-1300

10.1002/alr.21828 | PMID 27463614 Get It

BackgroundChronic invasive fungal sinusitis (CIFS) is a rare subtype of mycotic diseases involving the paranasal sinuses. It is characterized by a slow onset and invasive organisms with non‐granulomatous inflammation seen on histopathology. Historically, treatment has involved radical surgical resection. The purpose of this study was to describe the presentation, comorbidities, and role of more conservative treatment options.MethodsThis is a multi‐institutional retrospective case series of 6 patients with CIFS over 15 years. Patients’ medical comorbidities, imaging results, operative procedures, pathological findings including organisms identified, antimicrobial medications used, and outcomes were reviewed.ResultsThe mean time from onset of symptoms to diagnosis was 6 months. Cultures and fungal PCR identified Aspergillus species in every case. All 6 patients were found to have systemic comorbidities, with many being diabetic. Imaging findings ranged from thickening of sinus mucosa to invasion of the orbit and skull base. Treatment included long‐term antifungal therapy and conservative endoscopic surgery in all but 1 patient, who had an open approach. Every patient was free of invasive fungal disease at last follow‐up, with a range of 1 to 27 months.ConclusionCIFS is an insidious disease often with months between symptom onset and diagnosis. It is differentiated from chronic granulomatous invasive fungal sinusitis (CGIFS) by a lack of granulomas on histopathology and an association with diabetes mellitus. Endoscopic debridement combined with long‐term oral voriconazole was an effective treatment strategy in this series.
Utility of an Ultrasonic Aspirator in Transcanal Endoscopic Resection of Temporal Bone Paraganglioma
O’Connell, Brendan P., Hunter, Jacob B. , Carlson, Matthew David, Isaacson, Brandon , Wanna, George B. , Rivas, Alejandro , Hunter, Jacob B

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | July 26, 2016 | Volume: 78 | Issue: 01 | Pages: 096-098

10.1055/s-0036-1585090 | PMID 28180050 Get It

Abstract 3313: Pharmacologic targeting of Aurora-A kinase restores ERα expression and endocrine sensitivity through impairment of breast cancer stemness
D’Assoro, Antonino B. , Haddad, Tufia C. , Kuffel, Mary J., Hawse, John R. , Salisbury, Jeffrey L., Goetz, Matthew P. , Suman, Vera J. , Ingle, James N. , Galanis, Evanthia

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 3313-3313

10.1158/1538-7445.am2016-3313 Get It

Abstract Background: Intrinsic resistance has been linked to ER down-regulation and poor clinical outcome in breast tumors. Aurora-A kinase (AURKA) promotes distant metastases through activation of epithelial to mesenchymal transition (EMT) programming and expansion of breast tumor initiating cells (BTICs) harboring a CD44high/CD24low phenotype. Moreover, AURKA induces down-regulation of ERα expression and resistance to endocrine therapy that is mediated by SMAD5 transcription factor (D’Assoro et al., Oncogene 2014: 33:599-610). The aim of this study was to evaluate the role of AURKA in endocrine resistance induced by breast cancer stemness and ER down-regulation. Materials and Methods: We employed parental MCF-7 and variant MCF-7 cells ex-vivo (vMCF- 7/LCC9, vMCF-7/FR) that have high endogenous levels of AURKA, are ERlow, and exhibit in vivo resistance to fulvestrant. Real-Time Cell Proliferation and Apoptosis assays were performed to assess response to endocrine and/or AURKA-targeted therapy using the innovative IncuCyte ZOOM System. Stemness activity was assessed by culturing breast cancer cells under non-adherent conditions to generate mammospheres. Expression of ER, CD44 and CD24 markers was characterized by FACS analysis and immunofluorescence. Results: Pharmacologic inhibition of AURKA activity with the small molecule, alisertib, significantly restored sensitivity to fulvestrant in vMCF-7/LCC9 and vMCF-7/FR cells. To establish whether fulvestrant resistance was linked to enrichment of BTICs, breast cancer cells were cultured under non-adherent conditions to generate mammospheres. vMCF-7/FR cells generated mammospheres at higher efficiency compared to parental cells suggesting that vMCF-7/FR cells exhibited high self-renewal activity. vMCF-7/FR-derived mammospheres displayed a stem cell-like CD44high/CD24low phenotype that was further characterized by low levels of ER expression and resistance to fulvestrant. When vMCF-7 FR-derived mammospheres were treated with alisertib alone or combined with fulvestrant, the combination was more effective in mediating restoration of endocrine sensitivity. The phenotype of the alisertib-treated mammospheres was functionally linked to loss of CD44 expression, restoration of CD24 and ER expression, and sensitivity to fulvestrant. Conclusions: These findings provide further evidence that AURKA activity plays a central role in breast cancer progression through the genesis and clonal expansion of BTICs that are characterized by ER down-regulation and resistance to endocrine therapy. These results are important for the treatment of endocrine resistant breast tumors because they provide the rationale for the development of an innovative therapeutic approach to combine endocrine therapy with a targeted inhibitor of AURKA activity. Citation Format: Antonino B. D’Assoro, Tufia Haddad, Matthew Goetz, Mary Kuffel, John Hawse, Vera Suman, Jeffrey Salisbury, James Ingle, Evanthia Galanis. Pharmacologic targeting of Aurora-A kinase restores ERα expression and endocrine sensitivity through impairment of breast cancer stemness. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3313.
Abstract 3298: Distinct microbiome populations within breast cancer microenvironments
Thompson, Kevin J. , Sinnwell, Jason P. , Tang, Xiaojia , Ingle, James N. , Goetz, Matthew P. , Kalari, Krishna R.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 3298-3298

10.1158/1538-7445.am2016-3298 Get It

Abstract INTRODUCTION: The tumor microenvironment consists of a complicated interplay between a heterogeneous mixture of tumor cells and the surrounding tissue and there is a burgeoning interest in the role of the tissue microbiota within this microenvironment. Our group has investigated the breast tumor microbiome using the unaligned (non-human) reads from 796 RNASequencing data obtained from The Cancer Genome Atlas (TCGA) repository of Breast Cancer. METHODS: Unmapped sequences for 720 TCGA tumor samples and 76 paired normal samples were analyzed with Kraken v0.10.5 using the RefSeq 16S and standard genomes. To minimize false discoveries Kraken results were filtered to species that have bacterial genomic and 16S read support. Cluster analysis of the T-distributed Stochastic Neighbor Embedding (tsne) was performed and consensus voting of 26 maximum scoring metrics identified 3 distinct clusters. Differential abundance analysis was performed with the edgeR package. Covariate association analysis was performed for tumor clinical characteristics, as well as sample heterogeneity characteristics. RESULTS: There were three microbiome clusters we identified using TCGA breast samples. The average silhouette width of the third cluster was deemed statistically insignificant (0.071), suggesting further stratification of this cluster is necessary. The remaining two TCGA clusters (467) shared an average silhouette width of 0.39, using Bray's dissimilarity index. Differential abundance analysis of the two clusters after Bonferroni correction identified 450 significant species. The biomes were represented by 63 triple negative, 93 HER2+, 258 Luminal, and 50 tumor adjacent normals. Concordant cluster assignment was observed in 93.7 +/- 7.3% of the normal-tumor pairings, averaged across clinical subtypes. We observed clear delineation of biome populations at the order taxonomic level, which was not associated with the clinical subtype or the tumor/tumor adjacent pairings. We found enrichment of Burkholderiales in the first biome and enrichment of Bacillales and Lactobacillales within the second biome. The second biome appears to be deplete of representatives from the Asian population (p value 0.005) and survival associations were observed to be significantly reduced for HER2 patients associated with Biome 1 (p value 0.025). Geneset enrichment analysis of the expression signatures indicated drug metabolism and chemical carcinogenesis pathways to be associated with biome 2. CONCLUSIONS: In our study, we observed two significantly different microbiomes among TCGA breast cancer samples that were not associated with the clinical subtypes. Current efforts include validating these biomes, using 16S sequencing on matching fresh frozen paraffin embedded samples. Additionally, we are evaluating the influence of the biomes in independent adjuvant and neo-adjuvant studies with next generation sequencing data. Citation Format: Kevin J. Thompson, Jason Sinnwell, Xiaojia Tang, James N. Ingle, Matthew P. Goetz, Krishna R. Kalari. Distinct microbiome populations within breast cancer microenvironments. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3298.
Abstract 3424: Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer
Vachon, Celine M. , Jensen, Matthew R. , Brandt, Kathleen R. , Mahmoudzadeh, Amir Pasha , Whaley, Dana H. , Wu, Fang , Heine, John , Engmann, Natalie J. , Vachon, Celine M. , Scott, Christopher G. , Malkov, Serghei , Hruska, Carrie B. , Wu, Fang F., Winham, Stacey J. , Miglioretti, Diana L. , Norman, Aaron D. , Shepherd, John , Pankratz, V. Shane , Kerlikowske, Karla

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 3424-3424

10.1158/1538-7445.am2016-3424 Get It

Abstract Breast density represents the stromal and epithelial tissue in the breast and is a strong risk factor for breast cancer. Reductions in breast density attributable to tamoxifen (TAM) and aromatase inhibitors (AI) may be associated with reduced risk of first primary and subsequent breast cancer. Studies assessing breast density changes have principally used two-dimensional measures. We assess changes in breast density following initiation of TAM and AI using two automated volumetric density measures that have shown strong associations to breast cancer risk. Breast cancer cases with a full field digital mammogram (FFDM) prior to diagnosis (index mammogram) and after initiation of TAM (n = 379) or AI (n = 425) were identified from the Mayo Clinic Mammography Practice and the San Francisco Mammography Registry. Volumetric percent density (VPD) and dense volume (DV) were measured on 4-view FFDM using VolparaTM (Matakina Technology) and QuantraTM (Hologic) automated software. We used linear regression to assess the effect of treatment on mean annualized change in VPD and DV (change from index to last mammogram divided by time interval) for each software type, adjusting for age, body mass index (BMI) and density at index mammogram. The median time between index mammogram and cancer diagnosis was 0.6 months (IQR: 0.2, 2.2) and median time between index and last mammogram was 3 years (IQR: 2.0, 3.9). Women on TAM were younger, had lower BMI and higher baseline VPD and DV relative to women on AI (Table). An annual decrease in VPD and DV was observed with both TAM and AI. Both Volpara and Quantra estimated a similar magnitude of change in VPD in women on TAM and AI, and a greater change in DV with TAM. Our findings suggest that both Volpara and Quantra can assess volumetric changes in breast density among women on hormone therapy. If declines in volumetric density correlate with a reduction in breast cancer risk, these automated measures could be used in clinical practice to assess response to therapy. Annualized changes in volumetric breast density estimated by linear regression.Tamoxifen (n = 379)Aromatase Inhibitors (n = 425)Baseline Median (IQR)Annualized Change (95% CI)*Baseline Median (IQR)Annualized Change (95% CI)*Age at Diagnosis50.0 (45.0, 60.0)–63.0 (58.0, 71.0)–Body Mass Index (BMI)23.6 (21.5, 26.8)–25.7 (22.7, 29.9)–Time Interval¥3.0 (2.1, 3.9)–3.0 (2.1, 3.9)–VolparaPercent Density (VPD,%)11.6 (6.8, 18.8)-0.17 (-0.27, -0.10)7.2 (5.0, 11.0)-0.19 (-0.29, -0.12)Dense Volume (DV, cm3)64.7 (45.4, 90.9)-0.90 (-1.45, -0.48)51.9 (38.9, 69.9)-0.52 (-0.93, -0.23)QuantraPercent Density (VPD,%)14.5 (9.2, 20.2)-0.42 (-0.59, -0.28)9.9 (7.1, 14.5)-0.38 (-0.54, -0.25)Dense Volume (DV, cm3)94.0 (58.0, 144.0)-2.20 (-3.52, -1.19)80.0 (49.0, 128.0)-0.95 (-1.85, -0.35)IQR = Interquartile range ¥ Median number of years between index mammogram and last mammogram post-initiation of therapy. *Annualized change estimated as change from index to last mammogram divided by time interval and adjusted for study site, age at diagnosis, BMI and density at index mammogram. Citation Format: Natalie J. Engmann, Celine M. Vachon, Christopher G. Scott, Matthew R. Jensen, Lin Ma, Kathleen R. Brandt, Amir P. Mahmoudzadeh, Serghei Malkov, Dana H. Whaley, Carrie B. Hruska, Fang F. Wu, Stacey J. Winham, Diana L. Miglioretti, Aaron D. Norman, John J. Heine, John Shepherd, V Shane Pankratz, Karla Kerlikowske. Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3424.
Abstract 1762: Body mass index shows etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin
Breitenstein, Matthew K. , O’Byrne, Megan M., Thompson, Carrie A. , Macon, William R. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 1762-1762

10.1158/1538-7445.am2016-1762 Get It

Abstract Background. DLBCL is the most common non-Hodgkin lymphoma (NHL) subtype in western countries and is known to be clinically heterogeneous. Gene expression profiling has identified two major, biologically distinctive DLBCL subtypes on the basis of their cell-of-origin (COO): the germinal center B-cell (GCB) - characterized by BCL2 rearrangement and C-REL amplification, and activated B-cell (ABC) - characterized by constitutive activation of the NF-kB pathway. Recently, the InterLymph Subtypes Project identified medical history, lifestyle, and family history risk factors for DLBCL using a large pooled analysis of case-control studies. In this study we evaluated these same risk factors for etiologic heterogeneity as defined by DLBCL COO. Methods. For this analysis we used a clinic-based study of newly diagnosed NHL cases and frequency matched controls, enrolled from 2002-2012, with 474 DLBCL cases and 2203 controls. COO was determined clinically using the Hans algorithm, which is based on immunohistochemistry markers using formalin-fixed, paraffin-embedded tumor tissue. Amongst DLBCL cases 107 were ABC, 207 were GCB, and 160 were missing subtype (tissue unavailable). Risk factor data, including body mass index (BMI), smoking, alcohol use, any allergy, asthma, blood transfusion, diabetes, rheumatoid arthritis, sun exposure, lived on a farm and family history of hematologic malignancy, were collected from self-administered questionnaires. Polytomous logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals for ABC and GCB subtypes, adjusted for age and sex. Results. The mean age of cases was 60.4 years with 53% male; the mean age of controls was 61.6 years and 53% male. We identified a strong positive association for BMI with risk of ABC but not GBC DLBCL (p-heterogeneity 0.025). Compared to BMI 18.5-24.9 kg/m2, those with a BMI of 25.0-29.9 (OR = 1.65; 0.93-2.93) or 30+ (OR = 2.61; 1.48-4.62) were at increased risk of ABC DLBCL. There was no association for a BMI of 25.0-29.9 (OR = 0.91; 0.63-1.31) or 30+ (OR = 1.21; 0.83-1.76) with GCB DLBCL. There was no evidence of significant heterogeneity between ABC and GCB DLBCL for the other risk factors that we evaluated. Further adjustment of the BMI association for educational level, smoking, and alcohol only slightly attenuated these findings. Conclusions. We observed a strong positive association of BMI with ABC but not GCB DLBCL. In contrast, other evaluated risk factors showed no heterogeneity by COO. While BMI has not been clearly associated with NHL overall, there has been evidence for an association with DLBCL. The etiologic heterogeneity we observed for ABC DLBCL is notable as BMI is also a strong risk factor for multiple myeloma, another post-germinal center B-cell malignancy. While requiring replication, our findings suggest BMI may influence B-cell neoplasia through effect on post-germinal center pathways. Citation Format: Matthew K. Breitenstein, Megan M. O’Byrne, Andrew L. Feldman, Carrie A. Thompson, William R. Macon, Grzegorz S. Nowakowski, Stephen M. Ansell, Susan L. Slager, Thomas M. Habermann, James R. Cerhan. Body mass index shows etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1762.
Abstract 2593: Association of mammographic density measures and breast cancer ‘intrinsic’ molecular subtypes
Visscher, Daniel W., Shepherd, John, Chen, Yunn‐Yi , Beck, Andrew H. , Vachon, Celine M. , Norman, Aaron D. , Tamimi, Rulla M. , Scott, Christopher G. , Bertrand, Kimberly A. , Jensen, Matthew R. , Couch, Fergus J. , Fan, Bo, Pankratz, V. Shane , Kerlikowske, Karla , Vachon, Celine M.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 2593-2593

10.1158/1538-7445.am2016-2593 Get It

Abstract Percent mammographic density (PMD) is a risk factor for estrogen receptor (ER)-positive and ER-negative invasive breast cancer (BC). Gene expression profiling has identified molecular signatures that classify invasive BC into distinct subtypes that vary in their clinical behavior, response to treatment and likely, etiology. Immunohistochemical (IHC) staining of tumor sections using antibody panels can be used to classify these ‘intrinsic’ molecular subtypes. We evaluated whether density measures [PMD, absolute dense area (DA) and non-dense area (NDA)], are associated equally with all ‘intrinsic’ molecular subtypes. Pooled analysis of six cohort or case-control studies included 3492 women with invasive BC and 10,148 without, who underwent screening mammography a median 4 years prior to diagnosis (for cases). PMD, DA, and NDA were assessed from digitized film-screen mammograms using a computer-assisted thresholding technique, and categorized as 0-10%, 11-25%, 26-50% and 51%+ (PMD) or into quartiles (DA and NDA). Receptor status was abstracted from pathology records and supplemented by IHC staining. We classified tumors as Luminal A (ER+ and/or PR+ and HER2- and grade 1 or 2), Luminal B (ER+ and/or PR+ and HER2+ or Luminal A and grade 3), HER2 expressing (HER2+/ER-/PR-) and triple negative (TN) (ER-/PR-/HER2-). For TN, we also differentiated basal-like tumors (positive for EGFR and/or CK 5/6) from unclassified (negative on both markers). We used polytomous logistic regression to calculate the odds ratio (OR) of each ‘intrinsic’ subtype of BC by categories of PMD, DA or NDA, adjusting for age, body mass index and study. We tested for statistical heterogeneity of associations by subtype. Of 3492 invasive BC cases, 2217 (63%) were classified as Luminal A, 747 (21%) as Luminal B, 159 (5%) as HER2 expressing, and 369 (11%) as TN. Of TN, 203 were evaluated for CK 5/6 and EGFR, with 167 (82%) classified as basal-like and 36 (18%) unclassified. PMD was associated with BC risk across all subtypes. For Luminal A, compared to women with 11-25% PMD (reference), women with 0-10% had a reduced risk of BC (OR = 0.63 [95% confidence interval: 0.55, 0.74]) while women with 26-50% had an OR = 1.5 [1.3, 1.7] and women with 51%+ had the highest risk, OR = 2.3 [2.0, 2.7]. Similar BC associations were seen across PMD categories when comparing the five subtypes (P-heterogeneity = 0.63). Similar trends were seen for DA and BC across the five subtypes (P-het = 0.25). NDA was inversely associated with BC across subtypes, and there was suggestion of a stronger inverse trend among HER2-expressing BC compared to other subtypes (P-het = 0.09). Our results suggest mammographic density measures are associated with all ‘intrinsic’ molecular subtypes. However, NDA may be more strongly inversely associated with HER2-expressing than other subtypes. Understanding the importance of density measures for BC subtypes has significance for subtype-specific risk models. Citation Format: Aaron D. Norman, Rulla M. Tamimi, Christopher G. Scott, Kimberly A. Bertrand, Matthew R. Jensen, Daniel W. Visscher, Fergus J. Couch, John Shepherd, Bo Fan, Yunn-Yi Chen, Lin Ma, Andrew Beck, Vernon S. Pankratz, Karla Kerlikowske, Celine M. Vachon. Association of mammographic density measures and breast cancer ‘intrinsic’ molecular subtypes. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2593.
Establishing an Ambulatory Telemedicine Service in a Urology Practice
Rivera, Marcelino , O’Neil, Daniel A. , Montpetit, Andrew, Gettman, Matthew T., Viers, Boyd R.

Mayo Clinic

Videourology™ | July 26, 2016 | Volume: 30 | Issue: 4 | Pages: No page available

10.1089/vid.2016.0006 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2016.0006.M1 sj-vid-1-vid-10.1089_vid.2016.0006